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Letter to the Editor
Impact of Quantitative Assessment
of Parkinson’s Disease-Associated
Symptoms Using Wearable Technology
on Treatment Decisions
We read with interest the report by Santiago et al. [1], demonstrating that clinician decision making regarding
the management of motor symptoms of Parkinson’s disease (PD) can be enhanced by home-based, continuous
objective measurement.
Within the UK National Health Service, we have also been using the Parkinson’s Kinetigraph (PKG) since
2015. Similar to the Santiago cohort, in routine care, physicians target PKG use in patients they believe continuous
objective measurement will improve the value of clinical encounters. With support from Parkinson’s UK, we have
carried out an evaluation of utility across seven centers from the Parkinson’s Excellence Network, comprising a
mix of local services and regional specialist neuroscience centers led by consultant neurologists, geriatricians or
Parkinson’s nurse specialists. Between July 2015 and July 2017, 256 evaluations were collated, which included
information for 209 individual patients relating to PKG impact on clinical decision making. User experience was
also assessed by telephone interviews in 155 patients.
Consistent with the findings of Santiago et al. [1], information from the PKG confirmed initial clinical judge-
ment in 54.5% of cases and provided additional information to inform the clinical decision in 45.5% cases.
Changes in decision making included ten patients where the PKG results prompted a treatment change when
clinical assessment alone suggested no changes were necessary, and 15 patients who went on to receive advanced
therapies (apomorphine, levodopa-carbidopa intestinal gel or deep brain stimulation) when titration of oral med-
ications was initially considered. Conversely, information from the PKG prompted clinicians to try other options
in 18 patients for whom advanced therapies were being considered. Patient feedback was favorable, with 98%
of patients reporting a positive/neutral user experience, most patients finding it simple to use.
Our audit findings replicate those of Santiago et al. [1] in a different healthcare setting, across multiple
and varied healthcare provider organizations. The consistency of our evaluation findings highlights the poten-
tial of utilizing home-based objective monitoring to facilitate medical management of patients between clinic
appointments [2], which holds promise for delivering true home-based care [3].
Camille Carroll (camille.carroll@plymouth.ac.uk), Christopher Kobylecki, Monty Silverdale, Chris Thomas
on behalf of the PKG audit group
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